Post-marketing surveillance of Inebilizumab in patients with NMOSD for long-term efficacy and safety

Post-marketing surveillance of Inebilizumab in patients with NMOSD for long-term efficacy and safety - Post-marketing surveillance of Inebilizumab in patients with NMOSD for long-term efficacy and safety

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044431

Enrollment

200

Registered

2021-06-04

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis optica spectrum disorder (including neuromyelitis optica)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who receive Uplizna

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety Occurrence of adverse events during the observation period Correlation factors of the safety Efficacy Relapse status during the observation period EDSS/FS Correlation factors of the efficacy	—

Countries

Japan

Contacts

Public ContactKyoko Kato

Tanabe Pharma Corporation Pharmacovigilance Department

tp-pms-shinchoku.JP@ml.tanabe-pharma.com06-6205-5223

Outcome results